Skip to content

Alleviating Kidney Stone Burden in Patients with Enteric Hyperoxaluria

In This Article

  • Sagar U. Nigwekar, MD, MMSc, and colleagues have evaluated the kidney stone burden of patients with enteric hyperaxoluria
  • Out of the 33 subjects they observed, approximately 80% (around 27) had kidney stones
  • Nephrologists must be aware of enteric hyperoxaluria as a complication in patients who might have experienced gastrointestinal disorders or related procedures

A team led by Sagar U. Nigwekar, MD, MMSc, an assistant in Medicine in the Nephrology Division at Massachusetts General Hospital, has evaluated the kidney stone burden of patients with enteric hyperoxaluria. Their findings were presented during the American Society of Nephrology's Kidney Week 2018.

Dr. Nigwekar and his team studied 33 participants from three phase II studies to test the potency of ALLN-177. The patients observed each had enteric hyperoxaluria because of conditions or procedures such as gastric bypass surgery, Crohn's disease or short bowel syndrome.

Analysis of patient data revealed that as high as 80% of patients with enteric hyperoxaluria also had kidney stones. Many had stones in both kidneys, some had multiple stones in one kidney, and some had stones large enough to require clinical intervention.

Based on the findings above, Dr. Nigwekar emphasizes that nephrologists must be aware of enteric hyperoxaluria as a complication in patients who have undergone procedures such as gastric bypass surgery, as well as those who have experienced other gastrointestinal disorders such as short bowel syndrome. This awareness is crucial for alleviating patients' kidney stone burden.

Learn more about the Nephrology Division

Refer a patient to the Department of Urology

Related topics

Related

Dusting, a new protocol for treating kidney stones using recent laser technologies, has proven to deliver successful patient outcomes equal to those of traditional basketing, according to a study by the Endourology Disease Group for Excellence.

Related

Since the advent of targeted cancer therapies in the mid-2000s, there has been a dramatic reduction in cytoreductive nephrectomies. Dr. Michael Blute of Massachusetts General Hospital states that the reduction is concerning, since cytoreductive nephrectomy can provide a strong survival advantage to patients with metastatic disease.